Clinical Trials

miRagen has two product candidates in clinical development:

  • Cobomarsen (MRG-106), an inhibitor (LNA antimiR®) of microRNA-155, is being developed for the treatment of blood cancers;
  • MRG-201, a synthetic microRNA mimic (promiR) of microRNA-29b is being developed for the treatment or prevention of pathologic fibrosis;

For detailed trial information, please click here.